熱門資訊> 正文
InterCure报告1H结果
2024-08-30 21:09
- InterCure press release (NASDAQ:INCR): 1H Revenue of 126M New Israeli Shekels (NIS)
- Adjusted EBITDA for the six months ending June 30, 2024 was NIS 21M.
- The company's operating profit was NIS 11M.
- The October 7th terror attack effected the Company’s revenues in first half of 2024 due to damages to its southern facility located at Kibbutz Nir Oz.
- Expects double digit growth throughout the second half of 2024 compared to first half of 2024.
More on InterCure
- InterCure: A Cannabis Industry Leader Still Flying Under The Radar
- Financial information for InterCure
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
